0001055726-23-000005.txt : 20230228
0001055726-23-000005.hdr.sgml : 20230228
20230228174200
ACCESSION NUMBER: 0001055726-23-000005
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230226
FILED AS OF DATE: 20230228
DATE AS OF CHANGE: 20230228
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: KIES PETER
CENTRAL INDEX KEY: 0001259780
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-14888
FILM NUMBER: 23687803
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: INOVIO PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001055726
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 330969592
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6769 MESA RIDGE RD.
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 8584103134
MAIL ADDRESS:
STREET 1: 6769 MESA RIDGE RD.
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER COMPANY:
FORMER CONFORMED NAME: INOVIO BIOMEDICAL CORP
DATE OF NAME CHANGE: 20050404
FORMER COMPANY:
FORMER CONFORMED NAME: GENETRONICS BIOMEDICAL CORP
DATE OF NAME CHANGE: 20011116
FORMER COMPANY:
FORMER CONFORMED NAME: GENETRONICS BIOMEDICAL LTD
DATE OF NAME CHANGE: 19980213
4
1
wf-form4_167762408938905.xml
FORM 4
X0306
4
2023-02-26
0
0001055726
INOVIO PHARMACEUTICALS, INC.
INO
0001259780
KIES PETER
C/O INOVIO PHARMACEUTICALS, INC.
6769 MESA RIDGE ROAD
SAN DIEGO
CA
92121
0
1
0
0
CFO
Common Stock
2023-02-26
4
M
0
22544
A
201828
D
Common Stock
2023-02-26
4
F
0
12928
1.28
D
188900
D
Common Stock
2023-02-26
4
M
0
47967
A
236867
D
Common Stock
2023-02-26
4
F
0
28195
1.28
D
208672
D
Common Stock
4500
I
By Spouse
Restricted Stock Unit
2023-02-26
4
M
0
22544
0
D
Common Stock
22544.0
22544
D
Restricted Stock Unit
2023-02-26
4
M
0
47967
0
D
Common Stock
47967.0
95933
D
Common Stock Option
1.24
2023-02-27
4
A
0
225000
0
A
2023-02-27
2033-02-27
Common Stock
225000.0
225000
D
Each restricted stock unit represents a contingent right to receive one share of common stock. On February 26, 2021, the reporting person was granted 67,633 restricted stock units, vesting as follows: 22,545 shares vested on February 26, 2022; 22,544 shares vested on February 26, 2023; and 22,544 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (1) herein.
Each restricted stock unit represents a contingent right to receive one share of common stock. On February 26, 2022, the reporting person was granted 143,900 restricted stock units, vesting as follows: 47,967 shares vested on February 26, 2023; 47,967 shares will vest on February 26, 2024; and 47,966 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (3) herein.
The vesting schedule for the 225,000 options is as follows: 56,250 shares vested on February 27, 2023; 56,250 shares will vest on February 26, 2024; 56,250 shares will vest on February 26, 2025; and 56,250 shares will vest on February 26, 2026.
Peter Kies
2023-02-28